Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/rccm.202402-0458RL | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interleukin-22 promotes endometrial carcinoma cell proliferation and cycle progression via ERK1/2 and p38 activation.
Mol Cell Biochem
December 2024
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Endometrial carcinoma (EC) is one of the most common gynecological malignant tumors, but its underlying pathogenic mechanisms are largely obscure. Interleukin-22 (IL-22), one cytokine in the tumor immune microenvironment, was reported to be associated with carcinoma progression. Here, we aimed to investigate the regulation of IL-22 in endometrial carcinoma.
View Article and Find Full Text PDFAssociation of Inflammatory Factors with Cervical Cancer: A Bidirectional Mendelian Randomization.
J Inflamm Res
November 2024
Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Purpose: Persistent human papillomavirus infection is thought to be the main cause of the cervical cancer development along with inflammation. However, the potential mechanisms of action of the inflammatory factors in cervical cancer remain unclear. Therefore, this study aimed to assess the relationship between inflammatory factor levels and cervical cancer risk using a two-sample bidirectional Mendelian randomization (MR).
View Article and Find Full Text PDFInterleukin-22 improves ovulation in polycystic ovary syndrome via STAT3 signaling.
Mol Hum Reprod
October 2024
Department of Obstetrics and Gynaecology, State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Peking University Third Hospital, Beijing, China.
Article Synopsis
- Polycystic ovary syndrome (PCOS) is a common reproductive disorder in women that often results in irregular ovulation and impacts reproductive health.
- The study highlights that levels of interleukin-22 (IL-22), an immune factor, are lower in PCOS patients and positively influence follicle development and oocyte quality.
- Findings suggest that IL-22 works through its receptor and the STAT3 signaling pathway to enhance follicle growth and ovulation, indicating its potential as a new treatment approach for PCOS.
Human IL-22 receptor-targeted small protein antagonist suppress murine DSS-induced colitis.
Cell Commun Signal
October 2024
Laboratory of Ligand Engineering, BIOCEV Research Center, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, Vestec, 252 50, Czech Republic.
Article Synopsis
- Human interleukin-22 (IL-22) is a cytokine that plays a dual role in the body by maintaining intestinal health but can also contribute to chronic inflammation in diseases like inflammatory bowel disease (IBD) when overexpressed.
- Researchers developed small protein blockers to inhibit IL-22R1, using advanced techniques to identify effective binders through directed protein evolution and various screening methods.
- The study found that the best IL-22R1 antagonist, ABR167, successfully reduced inflammation in a mouse model of colitis, highlighting its potential as a therapeutic option for treating intestinal inflammation.
IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis despite Modulator Therapy.
Am J Respir Crit Care Med
November 2024
Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!